Status:
COMPLETED
Olopatadine Eye Drops and Allergy Skin Testing
Lead Sponsor:
Vanderbilt University Medical Center
Conditions:
Allergic Rhinitis
Allergic Conjunctivitis
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
Use of olopatadine ophthalmic solution (eye drops) will decrease allergy skin test reactivity.
Eligibility Criteria
Inclusion
- Adults aged 18 to 75 years
- Healthy volunteers (no major illnesses or active symptoms)
Exclusion
- Known allergy or hypersensitivity to the drugs or components
- Pregnant or nursing women
- Women wishing to become pregnant during the study's duration
- Use of topical or oral medications with antihistaminic activity for 14 days proceeding randomization
- Dermatographism as evidenced on skin testing on visit 1
- Chronic urticaria active within the past 6 months
- Severe hypertension
- Psychiatric diagnoses which could potentially affect medication compliance, such as schizophrenia or delusional disorders, as determined by the investigator obtaining informed consent and based on the subject's past medical history
- Inability to provide informed consent
Key Trial Info
Start Date :
January 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2008
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00775658
Start Date
January 1 2008
End Date
June 1 2008
Last Update
July 12 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vanderbilt Asthma, Sinus and Allergy Program Research
Nashville, Tennessee, United States, 37203